BIOLARGO (BLGO) Company Report

BioLargo's CEO, Dennis Calvert, outlined the company's strategy as an incubator-like model for technical assets, currently focused on monetizing investments across its portfolio.
The Cleara Medical asset, with $25 million invested, is valued at $100 million and projected to reach $500 million to $1 billion on exit, with product launch and final FDA paperwork expected in 3 to 6 months.
The PFAS technology, with $5 million invested, is valued at $60 million and projected to reach $750 million, with its first installation going live and a project pipeline exceeding $200 million.
The Odor and VOC business, which generated $15 million in revenue and $6 million in cash flow last year, has been impacted by a $4 million lawsuit related to the Pooph brand, leading to a valuation knockdown.
The company's market capitalization is approximately $50 million, but management contends it should be closer to $200 million, supported by $4 million in cash and no toxic debt.

Jan 22, 2026, 6:00 PM

BioLargo Highlights Key Asset Valuations and Market Opportunities

BLGO

New Projects/Investments

Legal Proceedings

Guidance Update

BioLargo (BLGO) operates as an incubator and investor in technical assets, focusing on sustainability and health, aiming to de-risk and partner technologies for market adoption.
The company's portfolio includes Clyra Medical (infection control), PFAS (forever chemicals elimination), ONM (odor and VOC), and battery technology.
Clyra Medical, with $25 million in invested capital and a current valuation of $100 million, is expected to launch products in the next three to six months and is anticipated to significantly impact BioLargo's economic profile.
The PFAS technology, 100% owned by BioLargo, has its first installation going live and a project pipeline exceeding $200 million, with the asset currently valued at $60 million.
The ONM asset, which generated $15 million last year, is involved in a $4 million lawsuit after terminating a license for the Pooph brand.

Jan 22, 2026, 6:00 PM

BioLargo Outlines Monetization Strategy and Asset Valuations

BLGO

New Projects/Investments

Legal Proceedings

Revenue Acceleration/Inflection

BioLargo is transitioning from an investment cycle to a monetization phase for its portfolio of de-risked technologies, which include Cleara Medical, PFAS solutions, and Battery Tech.
Cleara Medical, an infection control and wound care asset, has seen $25 million in total investment, is currently valued at $100 million, and is entering the market with a global partner, with BioLargo owning 49% and a 6% royalty.
The company's PFAS technology, which is 100% owned, has $5 million invested, is valued at $60 million, and is now in its first installation phase with a pipeline of over $200 million in projects.
Battery Tech, valued at $44 million, targets the multi-trillion-dollar grid-scale market by focusing on selling battery factories and leveraging project finance.
The Odor and VOC business, which previously generated $15 million in revenue and $6 million in cash flow, is currently impacted by a $4 million lawsuit and a terminated license for the Pooph brand, though the company anticipates repositioning.

Jan 22, 2026, 6:00 PM

BioLargo Revokes Pooph License Due to Payment Defaults

BLGO

Legal Proceedings

Profit Warning

Demand Weakening

BioLargo, Inc. has revoked the technology license granted to Pooph Inc. and is terminating their license agreement due to Pooph's failure to meet contractual obligations, including $3.8 million in payments owed.
Pooph Inc. was past due on $1,378,141 in royalties and $2,385,468 on product invoices as of June 6, 2025.
As a result of the termination, Pooph is no longer permitted to market or sell products that incorporate BioLargo's intellectual property.
BioLargo management is considering a substantial impairment to a $3,486,000 note receivable from Pooph Inc. on its balance sheet as of June 30, 2025, representing the amount due for royalties and product invoices.